Wilson will serve as vice president of the company's Advanced Radiopharmaceutical and Therapeutic Technologies business, with responsibilities that will include advancing the radioisotopes copper-67, actinium-225, and FibroScint (technetium-99m F4A), the last of which is partnered with Capella Imaging through commercial development.

In a statement, NorthStar said that the appointment is part of a broader reorganization that will also help expand the capacity and production of Mo-99. Wilson previously held the position of vice president, commercial operations, and has been with NorthStar for five years.